Review
Oncology
Maria I. Toki, Nikos Syrigos, Kostas Syrigos
Summary: This review summarizes the definitions, characteristics and current data on HPD, highlighting the controversies and lack of biomarkers for predicting this detrimental effect of immunotherapy. These challenges present difficulties for oncologists treating patients with ICIs.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Review
Biochemistry & Molecular Biology
Hugo Arasanz, Miren Zuazo, Ana Bocanegra, Luisa Chocarro, Ester Blanco, Maite Martinez, Idoia Morilla, Gonzalo Fernandez, Lucia Teijeira, Pilar Morente, Miriam Echaide, Natalia Castro, Leticia Fernandez, Maider Garnica, Pablo Ramos, David Escors, Grazyna Kochan, Ruth Vera
Summary: Immunotherapy has been positioned as a preferential treatment for a wide variety of neoplasms, but a new pattern of response called hyperprogressive disease, characterized by sudden tumor growth acceleration, has raised concerns. The identification of this phenomenon relies mostly on radiological criteria, with ongoing debate on whether it is induced by immunotherapy or reflects the natural course of highly aggressive tumors. Contradictory trial results among different cancer types suggest varying incidence, associated factors, and prognosis implications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Pharmacology & Pharmacy
Pan Shen, Liang Han, Xin Ba, Kai Qin, Shenghao Tu
Summary: Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has shown promise in treating cancer by leveraging the immune system, but some patients treated with ICIs may experience hyperprogressive disease (HPD) with unclear mechanisms.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Cell Biology
Zhanqi Wei, Yuewei Zhang
Summary: Immunotherapy has been widely studied and applied as a treatment for eliminating tumor cells by activating immune responses. Immune checkpoint inhibitors (ICIs) are effective in preventing immune responses from being turned off. However, the occurrence of hyperprogressive disease (HPD) during immunotherapy remains unclear.
Review
Nutrition & Dietetics
Xiaojun Liu, Liang Qiao
Summary: Immune checkpoint inhibitors (ICIs) have shown improved long-term survival in cancer patients, but a subset of nonresponsive patients may experience hyperprogressive disease (HPD), which is associated with poor prognosis. More precise parameters are needed to predict and evaluate the response pattern to ICIs.
FRONTIERS IN NUTRITION
(2022)
Review
Oncology
Stefania Angelicola, Francesca Ruzzi, Lorena Landuzzi, Laura Scalambra, Francesco Gelsomino, Andrea Ardizzoni, Patrizia Nanni, Pier-Luigi Lollini, Arianna Palladini
Summary: The mechanisms driving hyperprogressive disease (HPD) are still unknown, but IFN-γ and CD38 are proposed to play important roles in its development by affecting signaling pathways and responses to immune checkpoint inhibitor (ICI) therapy.
Article
Medicine, General & Internal
Hasan Cagri Yildirim, Deniz Can Guven, Oktay Halit Aktepe, Hakan Taban, Feride Yilmaz, Serkan Yasar, Sercan Aksoy, Mustafa Erman, Saadettin Kilickap, Suayib Yalcin
Summary: In this study, HPD was observed in 16.5% of patients treated with immunotherapy. High LDH level, hypoalbuminemia, and NLR > 5 were found to be associated with hyperprogression.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Immunology
Yanping Li, Tianhong Chen, Tian Yi Nie, Juyuan Han, Yunyan He, Xingxing Tang, Li Zhang
Summary: Immune checkpoint inhibitors (ICIs) effectively activate the anti-tumor immune function of T cells in non-small cell lung cancer patients by targeting the negative regulatory pathway of T cells. However, Hyperprogressive Disease, characterized by accelerated tumor growth and poor prognosis, poses a challenge to this promising immunotherapy. This review provides a comprehensive overview of Hyperprogressive Disease in ICIs-based immunotherapy for non-small cell lung cancer, including its definition, biomarkers, mechanisms, and treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Medicine, General & Internal
Hyo Jung Park, Kyung Won Kim, Sang Eun Won, Shinkyo Yoon, Young Kwang Chae, Sree Harsha Tirumani, Nikhil H. Ramaiya
Summary: HPD is a recognized pattern of rapid tumor progression during immune checkpoint inhibitor treatment. The incidence of HPD varies from 5.9% to 43.1% across studies examined. Definitions of HPD are diverse, indicating the need for establishing uniform criteria based on currently available evidence.
Article
Oncology
Chun-Hong Hu, Shenghao Shi, Wen Dong, Lizhi Xiao, Hongjing Zang, Fang Wu
Summary: Primary pulmonary enteric adenocarcinoma (PEAC) is a rare invasive adenocarcinoma similar to metastatic colorectal adenocarcinoma (MCRC). This report presents a case of a 61-year-old male patient with PEAC showing unresponsiveness to a combination chemotherapy regimen and immunotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Fabrizio Marcucci, Cristiano Rumio
Summary: Adaptive antitumor immune responses can sometimes promote tumor growth by causing expansion, resistance, proliferation, etc. Understanding these immune responses may help predict and counteract hyperprogressive diseases, suggesting the need for predictive biomarkers and therapeutic interventions.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Chang Gon Kim, Chan Kim, Sang Eun Yoon, Kyung Hwan Kim, Seong Jin Choi, Beodeul Kang, Hye Ryun Kim, Su-Hyung Park, Eui-Cheol Shin, Yeun-Yoon Kim, Dae Jung Kim, Hyun Cheol Chung, Hong Jae Chon, Hye Jin Choi, Ho Yeong Lim
Summary: HPD can occur in a fraction of HCC patients treated with PD-1 inhibitors, leading to worse survival outcomes and missed treatment opportunities for the majority of affected patients. Analyzing baseline immune profiles and tumor growth dynamics during treatment could help identify HPD earlier for optimal patient management.
JOURNAL OF HEPATOLOGY
(2021)
Article
Oncology
Odd L. Gammelgaard, Mikkel G. Terp, Christian Renn, Aran F. Labrijn, Oliver Hamaker, Aaraby Y. Nielsen, Henriette Vever, Soren Wk Hansen, Morten F. Gjerstorff, Christa E. Muller, Paul Whi Parren, Henrik J. Ditzel
Summary: The study demonstrates that combining different anticancer activities of anti-CD73 antibodies into a biparatopic bispecific antibody enhances enzyme inhibitory activity, alleviates T-cell suppression, and prolongs the survival of tumor-bearing mice. The bispecific antibody facilitates more efficient internalization of cell surface CD73 and stimulates Fc-mediated engagement of human immune effector cells in vitro and in vivo.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Romain Varnier, Thibaut Garrivier, Emilie Hafliger, Aymeric Favre, Clelia Coutzac, Clement Spire, Pauline Rochefort, Matthieu Sarabi, Francoise Desseigne, Pierre Guibert, Anne Cattey-Javouhey, Pamela Funk-Debleds, Charles Mastier, Adrien Buisson, David Perol, Oliver Tredan, Jean-Yves Blay, Jean-Marc Phelip, Christelle de la Fouchardiere
Summary: This study presents a case of hyperprogressive disease in a 68-year-old patient with stage IV MSI-H gastric adenocarcinoma after receiving ICI treatment, highlighting the need for further research on predictive factors for hyperprogression in this subset of patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
M. Schuiveling, E. H. J. Tonk, R. J. Verheijden, K. P. M. Suijkerbuijk
Summary: Hypperprogression, characterized by rapid acceleration in tumor growth, is rare in melanoma patients treated with immune checkpoint inhibitors. The data raises questions about whether hyperprogression is truly a biological entity in metastatic melanoma.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Oncology
Jin-Sung Chung, Vijay Ramani, Masato Kobayashi, Farjana Fattah, Vinita Popat, Song Zhang, Ponciano D. Cruz, David E. Gerber, Kiyoshi Ariizumi
CLINICAL CANCER RESEARCH
(2020)
Article
Oncology
Mitchell S. von Itzstein, Shaheen Khan, Vinita Popat, Rong Lu, Saad A. Khan, Farjana J. Fattah, Jason Y. Park, Bonnie L. Bermas, David R. Karp, Murtaza Ahmed, Jessica M. Saltarski, Yvonne Gloria-McCutchen, Yang Xie, Quan-Zhen Li, Edward K. Wakeland, David E. Gerber
Article
Oncology
Vinita Popat, Rong Lu, Murtaza Ahmed, Jason Y. Park, Yang Xie, David E. Gerber
Article
Hematology
Abhishek Maiti, Hagop M. Kantarjian, Vinita Popat, Gautam Borthakur, Guillermo Garcia-Manero, Marina Y. Konopleva, Courtney D. DiNardo, Srdan Verstovsek, Michael Andreeff, Tapan M. Kadia, Helen O. Ajufo, Rohit Goswamy, Carlos Blanco, Miguel Velasquez, Naval G. Daver, Naveen Pemmaraju, Sherry R. Pierce, William G. Wierda, Steven M. Kornblau, Farhad Ravandi, Jorge E. Cortes
